Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.68 |
| ▸ | DRD4 | P21917 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8006961 | 0.81 | DRD2 (1.00) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL8008834 | 0.81 | DRD2 (0.80) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL8006320 | 0.81 | DRD2 (1.00) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL13729374 | 0.81 | DRD2 (1.00) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL7393183 | 0.80 | DRD2 (0.61) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL7996935 | 0.80 | DRD2 (0.61) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| Bromide SCHEMBL3786484 | 0.80 | DRD2 (0.97) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL13730744 | 0.79 | DRD2 (1.00) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL13729821 | 0.78 | DRD2 (0.72) | DRD2DRD4DRD3KCNH2SMN1; SMN2 | |
| SCHEMBL3787122 | 0.76 | DRD2 (0.53) | DRD2DRD4DRD3KCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254876-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | AstraZeneca AB (SE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009105026-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215841-A1 | D2 Receptor Ligand-078 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215841-A1 | D2 Receptor Ligand-078 | TACR2, TACR1, GPR174 | DRD2 39/4885DRD4 186/4885DRD3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.